Several months back, a Biosimilar focused subsidiary of a Global Pharma had appointed Aagami to help out-license their Market ready Denosumab Biosimilar for Japan. Eventually we supported them for broader regions too.
Happy with our work, now the client has awarded extension to Aagami and also expanded scope for licensing their other late stage biosimilars such as:
- Romiplostim (Nplate®) [ For immune thrombocytopenia (ITP) ]
- Teriparatide (Forteo®/Forsteo®) [ For Osteoporosis ]
- Liraglutide (Victoza®) [ For Diabetes ]
- Tocilizumab (Actemra®) [ For Rheumatoid arthritis (RA), Giant Cell Arteritis (GCA), Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), Active Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) and patients with coronavirus disease 2019 (COVID-19) receiving systemic corticosteroids and requiring supplemental oxygen or mechanical ventilation. ]
If you would like to know more about this, please contact us.